Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an ...

Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

FOR years, doctors told Lea Hughes that her common cancer symptom was simply caused by hormones – now she has tumours in her ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic breast cancer should know.

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

The companies said Enhertu is the first HER2-directed therapy to show a strong tumour response in this population, which accounts for 2% to 4% of all NSCLC cases. Image. Phil Taylor.

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Enhertu is part of a newer type of cancer treatment called antibody-drug conjugates (ADC). It works like a delivery system for medicine, even a "biologic missile." ...

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY ...

A Brit woman was given a shocking diagnosis of stage 4 breast cancer after she said her tumour was repeatedly dismissed as ...